And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. And our agenda is ambitious. We hope to noodle around the Pharmalot grounds, visit the Pharmalot ancestors and take in another installment of our ‘Let’s-see-them-before-they-die‘ concert series. And what about you? This is, as we regularly remind you, a fine time to enjoy the great outdoors. Perhaps, you could catch up on your reading or make time for someone special. Or you could tune out the real world and watch the Royal Wedding. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon…
Amgen (AMGN) will charge $6,900 a year for a new drug that can spare migraine sufferers a few headaches each month, a price well below Wall Street expectations as the company hopes to avoid payer backlash that has hamstrung recent drug launches, STAT reports. The drug, called Aimovig, is meant for patients who experience at least four migraines per month. There are roughly 24 million patients in the U.S. who would be candidates for treatment. The Institute for Clinical and Economic R, a nonprofit that assesses the value of medicines, pegged cost effectiveness at $8,500.
About the Author Reprints
